However, previous studies have reported that breast cancer is generally considered a low immune-reactive cancer, TNBC, the most aggressive subtype of breast cancer, but responds to anti-PD-1/PD-L1 immunotherapy (Adams et al., 2019b; Adams et al., 2019c). Here, CD274 is linked to breast carcinoma.